Kornimate/medical-research-clean huggingface dataset:
efficacy of adw s-100 ionized water nasal spray in decreasing symptoms of allergic rhinitis

Conditions: Allergic Rhinitis

Summary: a nasal spray based on advanced water s-100 ionized water would clean the nasal cavities, reduce the viscosity of mucus and facilitate its elimination and decongestion of the nose and the prevention of the bridging of the allergen to the epithelial cells of the cavity nose at the origin of the onset of symptoms. indeed, a water-based nasal spray ionized advanced water s-100 would modify the electrostatic environment of all the interactions ensuring this bridging. negative ions (oh-) contained in water ionized advanced water s-100 competes with negative ions from acids negatively charged amino acids and also neutralize basic amino acids positively charged. the destabilization of all the links governing the process of epitope/ige association would prevent the bridging of the fcɛri receptors of the mast cell and thus the cascade of cellular responses that cause symptoms. the purpose of this study is to assess whether the use of ionized water nasal spray adw s-100 allows to sufficiently reduce the intensity of the symptoms of allergic rhinitis and thus improve the quality of life of people with allergies.


Eligibility criteria:
inclusion criteria: 1. men and women ≥ 18 years old 2. inform consent 3. beneficiaries of a social security scheme 4. having documented persistent or intermittent allergic rhinitis for at least 2 years 5. in the respiratory environment allergen battery, at least one prick-test positive at selection (diameter \>3mm compared to the negative control), or prick-test or specific ige assay less than 6 months old demonstrating an allergic response appropriate 6. agreeing not to take anti-allergic drug treatment during the duration of the study except in case of aggravation of the disease 7. having a smartphone or a computer allowing access to the application of seizure to be eligible to be randomized, participants must have: 8. used the nasal spray at least 2 times a day during the run-in, according to their answers on the application 9. a median vas for the evaluation of the discomfort due to the symptoms of the selection at d-1 ≥ 50mm non-inclusion criteria: 1. existence of links with any member of the study staff or the sponsor, or conflicts interests with the promoter 2. known hypersensitivity or allergy to one of the components of the product tested 3. contraindication to the use of a nasal spray 4. respiratory pathology other than allergic rhinitis/rhino-conjunctivitis and asthma mild or moderate. people with severe asthma may be included if their asthma is controlled 5. current treatment with systemic corticosteroids 6. known pregnancy or positive urine pregnancy test at screening and/or at d0, or breastfeeding in progress 7. participation in a clinical trial or other clinical investigation using a device medicine for the treatment or prevention of rhinitis or conjunctivitis
endoscopic radiofrequency ablation for unresectable cholangiocarcinoma

Conditions: Cholangiocarcinoma; Klatskin Tumor; Bile Duct Cancer; Liver Cancer

Summary: the goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting. the main questions it aims to answer are: * does radiofrequency ablation of tumorous bile duct occlusion reduce risk of complications in these patients (eg stent dysfunction, delay of chemotherapy, infections etc)? * is radiofrequency ablation safe in these patients? all participants will receive standard treatment with systemic chemotherapy and bile duct stenting. researchers will compare two groups (one group will receive additional radiofrequency ablation, the other not).


Eligibility criteria:
inclusion criteria: 1. unresectable perihilar and/or ductal cca with bile duct stenting and palliative systemic therapy as indicated by the local multidisciplinary team (mdt) 2. written informed consent 3. eastern cooperative oncology group (ecog) performance status 0-1 4. age ≥18 years 5. eligibility for palliative systemic therapy based on clinical and laboratory parameters (except hyperbilirubinemia) as determined by the local mdt 6. no prior radiofrequency ablation (rfa) for cca 7. no repeated bile duct stenting in the past 3 months (trial inclusion is possible upon first stent replacement or initial stent placement within past 3 months) 8. no concomitant disease or malignancy interfering with the study procedure or efficacy outcome measures, particularly no severe or uncontrolled cardiovascular disease (congestive heart failure nyha iii or iv, unstable angina pectoris, myocardial infarction within ≤3 months, significant arrhythmias) and no psychiatric disorders precluding understanding of information of trial related topics and giving informed consent

Keywords: radiofrequency ablation intraductal biliary endoscopic retrograde cholangiography transpapillary stent dysfunction cholangitis obstruction
early detection of hcv in injection drug users

Conditions: Hepatitis C Virus Infection

Summary: the project is a national, prospective, multicenter, non-interventional pilot project of screening hcv in pwid in the czech republic. the main goal of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of hepatitis c and setting up and testing new methods and implementation into the system of social health care.

the project is a national, prospective, multicenter, non-interventional pilot project of screening hcv in pwid in 18 clinical centers in the czech republic. the main goal of the project is the elimination of further transmission of hepatitis c virus and to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of hepatitis c and setting up and testing new methods and implementation into the system of social health care. the project will include testing the procedure on a sample of approx. 3,000 pwid which can help to identify weak points in the continuum of care. a methodology for the continuous care of the target group in the early diagnostic and therapeutic stages will be created. proposal for a system change towards streamlining the screening process. the project is supported by the european social fund (operational program employment plus) and the state budget of the czech republic and is registered by the ministry of labour and social affairs of the czech republic under id: cz.03.02.02/00/22_005/0000281.

Eligibility criteria:
inclusion criteria: * age 18+ * an active injecting drug user or have used injecting drugs at any time in the past exclusion criteria: * not agreeing to participate in the project

Keywords: hcv pwid point of care testing hepatitis czech republic hcv genotype
study of the safety and efficacy of fixed dose opc-34712 as adjunctive therapy in the treatment of adults with major depressive disorder (the pyxis trial)

Conditions: Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders

Summary: to compare the effect of opc-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned fda approved antidepressant treatment (adt) in patients with major depressive disorder who demonstrate an incomplete response to a prospective trial of the same assigned fda approved adt


Eligibility criteria:
inclusion criteria: * male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by dsm-iv-tr criteria * the current depressive episode must be equal to or greater than 8 weeks in duration * subjects must report a history for the current depressive episode of an inadequate response to no more than three adequate antidepressant treatments exclusion criteria: * females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug * subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration. * subjects with a current axis i (dsm-iv-tr) diagnosis of: delirium, dementia, amnestic or other cognitive disorder, schizophrenia, schizoaffective disorder, or other psychotic disorder, bipolar i or ii disorder * subjects with a clinically significant current axis ii (dsm-iv-tr) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder

Keywords: opc-34712 brexpiprazole major depressive disorder adjunctive treatment
different lipid soluble opioids for gynecologic laparoscopic surgery postoperative patient-controlled analgesia

Conditions: Post Operative Pain Management

Summary: the investigators noticed that body fat ratio might have great influence on the efficacy of different lipid soluble anesthetics. the objective of this clinical trial was to compare the effect of that body fat ratio on the efficacy of different lipid soluble anesthetics.

the objective of this clinical trial was to compare the effect of that body fat ratio on the efficacy of different lipid soluble anesthetics.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists grade i-ii * adults aged over 20 and below 50 years old, * non-smoker, * with normal hepatic and renal function. exclusion criteria: * smoker , * any kind of mental disorder or * history use of analgesics for more than 10 consecutive days, * asthma; and * those with digestion tract disorder who would get nausea or vomiting much more easily than normal people.

Keywords: sufentanil morphine postoperative pain control body fat percentage gynecology laparoscopic surgery lipid solubility
comparison of the duration of ropivacaine combined with dexmedetomidine or dexamethasone on paravertebral block

Conditions: Lung Cancer

Summary: this study was a prospective, randomized, controlled, and double-blind trial. major assessments were made during the operation and 48 h postoperatively.

the prime outcomes were the time in minutes from leave the postoperative care unit to the first patient-controlled intravenous analgesia press.the secondary outcomes were to compare the following: (1)blood concentrations of ropivacaine was measured at 0.5 h, 1 h, 2 h, 3 h, and 24 h after paravertebral nerve block; and (2) the patient's intraoperative opioid use, phenylephrine use, fluid intake, urine output, dry mouth score, and 24 h and 48 h visual analogue scale.

Eligibility criteria:
inclusion criteria: * (1) age 18 to 65 years, * (2) scheduled to undergo video-assisted thoracic surgery, * (3) american society of anesthesiologists risk classification i-ii. exclusion criteria: * (1) patient refusal; * (2) known hypersensitivity to the study medication (ropivacaine); * (3) long-term use of opioids; * (4) liver or renal insufficiency; * (5) a history of psychiatric or neurological disease; * (6) deafness; * (7) regular use of acetaminophen, nonsteroidal anti-inflammatory drugs, corticosteroids, or antiemetics; and * (8) a preoperative pittsburgh sleep quality index (psqi) global score higher than 6.
clinical efficacy of high-flow nasal cannula oxygen therapy in patients with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: patients meeting the criteria of obstructive sleep apnea were included, and all patients signed informed consent, which met the requirements of the ethics committee of our unit. all subjects were hospitalized patients. subjects were randomly enrolled into high-flow nasal cannula oxygen therapy group or continues positive airway pressure group for 3 days of treatment. sleep monitoring was performed on the first and fourth day of enrollment.


Eligibility criteria:
inclusion criteria: 1. there were typical symptoms of sleep snoring at night with apnea and daytime sleepiness (ess score ≥9). stenosis and obstruction in any part of the upper airway were observed on physical examination, with ahi≥5 times /h. 2. for patients with no significant daytime sleepiness (ess score \< 9), ahi≥10 times /h. 3. patients with ahi≥5 times /h had one or more osahs complications, such as cognitive impairment, hypertension, coronary heart disease, cerebrovascular disease, diabetes and insomnia. exclusion criteria: 1. patients who cannot tolerate non-invasive ventilator or transnasal high-flow oxygen therapy. 2. ongoing treatment may affect sleep, such as sedatives, hypnotics, muscle relaxants, etc. 3. hemodynamic instability. 4. severe respiratory diseases.

Keywords: continues positive airway pressure high-flow nasal cannula oxygen therapy
pharmacokinetics, effectiveness and tolerability of prolonged-release tacrolimus after paediatric kidney transplantation

Conditions: Pediatric Kidney Disease

Summary: recently, a new prolonged-release tablet version of tacrolimus (envarsus®) using the so-called meltdose™ (us patent no. 7,217,431) drug-delivery technology has been approved as immunosuppressive medication for patients after kidney and liver transplantation in adults but not yet in children. studies in adults proved that envarsus® provides the same therapeutic effectiveness as the conventional immediate-release tacrolimus formulation (prograf®) with improved bioavailability, a more consistent pharmacokinetic profile and reduced peak to trough which might result in reduced tacrolimus dosing and subsequently reduced cni related toxicity. furthermore, the once daily formulation might result in improved drug adherence. the aim of this study is to assess pharmacokinetic profiles of envarsus® as well as effectiveness and tolerability of this drug in children and adolescents ≥ 8 and ≤ 18 years of age.


Eligibility criteria:
inclusion criteria: 1. caucasian paediatric kidney transplant recipients (single-organ recipients) 2. aged ≥ 8 years but ≤ 18 years who are under tacrolimus (prograf®) therapy and who are able to swallow tablets with a minimum dose of 0.75 mg / day envarsus® 3. not less than 6 months after transplantation 4. stable kidney function (delta egfr \< 10 ml/min/1.73 m2 (ckid formula) over the last 3 months) 5. women of childbearing potential and women without childbearing potential 6. patient/parents/legal guardian(s) must be capable of understanding purpose and risks of the study 7. signed informed consent obtained by patient and parents/legal guardians exclusion criteria: 1. coefficient of variation of tacrolimus trough levels \> 0.35 over the previous 6 months 2. pregnancy/breast feeding 3. instable kidney function 4. hypersensitivity to any of the components of the medications used 5. not eligible for any reason according to the investigator's valuation 6. known positive hiv-1 or hcv test 7. participation in another clinical trial (other investigational drugs or devices at the time of enrolment or within 30 days prior to enrolment)
ischemia driven enoxaparin therapy in acs presenting as low risk (ideal)

Conditions: Unstable Angina

Summary: the purpose of this study is to determine whether enoxaparin (an anticoagulant) is effective in the treatment of patients presenting to the emergency room with chest pain and no electrocardiogram or bloodwork evidence of a heart attack, but with other high risk clinical features

patients with chest pain and abnormal electrocardiogram or bloodwork (biomarker) indicative of a heart attack benefit from anticoagulant therapy such as enoxaparin. however, even patients without abnormalities on the electrocardiogram or bloodwork are at increased risk for heart attack or death, if they have certain clinical risk factors. it is currently not known whether enoxaparin is also beneficial for these patients. comparison: enoxaparin in addition to optimal standard care at the discretion of the treating physician, versus optimal standard care without enoxaparin

Eligibility criteria:
inclusion criteria: * male or female (negative pregnancy test required for females of childbearing potential) ≥ 18 years of age and capable of signing informed consent; * typical chest discomfort at rest; lasting at least 5 minutes in the prior 24 hours that is highly suggestive of myocardial ischemia and is not explained by trauma or obvious abnormalities on chest x-ray; * two or more of high-risk clinical features. exclusion criteria: * clear indication for low molecular weight or unfractionated heparin; * pregnancy; * increased bleeding risk; * impaired hemostasis; * angina from a secondary cause; * inability to commence st segment monitoring within 4 hours of study drug initiation; * uninterpretable st segment based upon baseline 12-lead ecg; * any contraindications to treatment with lmwh (or unfractionated heparin), including heparin induced thrombocytopenia, known allergy to heparin, low molecular weight heparin, pork or pork products; * renal insufficiency or renal dialysis; * a prosthetic heart valve; * any other clinically relevant serious diseases; * current evidence of inebriation with alcohol or intoxication resulting from other drug abuse; * treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or has previously enrolled in this trial; * inability to comply with the protocol; * inability to understand the nature, scope, and possible consequences of the study or is otherwise unable to provide informed consent.

Keywords: unstable angina drug therapy myocardial ischemia myocardial infarction hemorrhage
high voltage pulsed current and microcurrent stimulation therapy in treatment of wounds.

Conditions: Wound; Ulcer

Summary: the purpose of this study is to evaluate the effectiveness of high-voltage pulsed current (hvpc) and microcurrent stimulation therapy (mst) in treating chronic wounds and to compare their effects.

sixty patients with chronic wounds (pressure ulcers) and their ages will be ranged from 45 to 60 years old. they will be recruited from the outpatient clinic at kasr al-aini hospitals and they will be randomly assigned into two groups of equal numbers, each one will contain thirty patients. high-voltage pulsed current group and microcurrent stimulation therapy groups. the change in wound surface area and wound volume will be measured before the intervention and after six weeks of intervention.

Eligibility criteria:
inclusion criteria: * patients are of both sexes. * subject's age will be from 45 to 60 years. * all patients will enter the study having their informed consent. * all patients will be assessed by a physician before starting the study procedure. * all patients suffer from a chronic wound not healed more than or within six weeks. exclusion criteria: * patients with acute wounds. * patients with burn wound injuries. * malignancy in the wound. * necrotic tissue in the wound.

Keywords: high-voltage pulsed current micro-current therapy chronic wound
effect of alternate therapies on intraocular pressure in ocular hypertension

Conditions: Ocular Hypertension

Summary: the purpose of this study is to evaluate the effect of complementary and alternative therapies, specifically alternate nostril breathing and foot reflexology, on intraocular pressure in patients with ocular hypertension.

11 patients were recruited from temple ophthalmology between 2014 and 2016. patients had ocular hypertension and were between the ages of 48-74. patients were excluded if they currently performed anb or fr, were unable to perform the task, had previous eye surgery or laser, were receiving other cam for ocular hypertension, or were unable to complete a washout period. after a 30-day drug washout, patients completed either anb or fr. after instruction, the assigned task was performed for 5 minutes. fr was done on a commercially available foot reflexology board (japan tsubo hh-700) focused at the base of the second and third toes of both feet. two weeks later, patients completed the alternate task. iop was measured before the task, immediately after the task and then every 30 minutes for two hours. sign rank tests were used to evaluate iop changes within and between each group.

Eligibility criteria:
inclusion criteria: * patients with ocular hypertension exclusion criteria: * currently performed alternate nostril breathing or foot reflexology * were unable to perform the task * had previous eye surgery or laser, * were receiving other cam for ocular hypertension * were unable to complete a washout period if they using glaucoma eye drops
study to evaluate the efficacy and safety of 0.1% and 0.03% tacrolimus ointment administered in adults with moderate to severe atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: the objective of this study is to assess the efficacy and safety of 0.1% and 0.03% tacrolimus ointment for 12 months in adults with moderate to severe atopic dermatitis.

the main phase is 6 months duration, but the follow up phase up to 12 months will allow the collection of efficacy and safety data in a period which will include all seasons in each patient, to account for seasonal variability which strongly affect atopic dermatitis course.

Eligibility criteria:
inclusion criteria: * patient may be male or female of any ethnic group * patient without restricted legal competence, and suffers from moderate to severe atopic dermatitis (rajka/langeland score of at least 4.5) * patient known to be responsive to topical steroids * patient is capable of understanding the purposes and risks of the trial and has given written informed consent * female patients of childbearing potential must agree to maintain adequate birth control practice during the trial period and during the first four weeks after the end of the study * patient meets the following criteria: * topical corticosteroids * systemic corticosteroids (for the treatment of ad only) * systemic non-steroidal immunosuppressants (e.g. cyclosporine, methotrexate) * other investigational drugs * light treatments (uva, uvb) * patient has not taken and agrees not to take for the complete study period any medication or therapy prohibited by the protocol exclusion criteria: * patient has a genetic epidermal barrier defect such as netherton's syndrome or generalised erythroderma * patient is pregnant or breast-feeding * patient has a skin infection on the affected (and to be treated) area * patient has a known hypersensitivity to macrolides in general, to tacrolimus or any excipient of the ointment * patient is simultaneously participating in any other drug trial or less than 28 days have passed between the end of the previous trial and this one * any form of substance abuse (including drug or alcohol abuse),psychiatric disorder or condition which, in the opinion of the investigator, may invalidate the communication with the investigator * patient is known to be hiv positive

Keywords: atopic dermatitis tacrolimus ointment